With approval target dates scheduled for two eye drugs, Aldeyra Therapeutics, Inc. is accelerating partnership plans for one of them and looking to going it alone for the other.
Aldeyra All Set For Double Date With The FDA
Secures PDUFAs For Two Eye Products
The US agency is reviewing two of the US biotech’s drug with decisions expected on its methotrexate product for ocular lymphoma by June and on the dry eye drug reproxalap in November, as Aldeyra mulls its marketing strategy for both.
More from Sensory
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus